Efficacy of inhaled DNase in admitted infants with RSV-bronchiolitis.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON20249

Enrollment

180

Registered

2005-07-04

Start date

2002-12-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Twice daily 2,5 mg DNase or placebo during admission.

Eligibility

Inclusion criteria

Inclusion criteria: 1. RSV bronchiolitis with need for additional oxygen (saturation ¡Ü 92 %); 2. RSV-infection proven with rapid assay or culture; 3. Age < 12 months ; 4. Admission on (medium care) ward; 5. Study medication can be started within 24 hours.

Exclusion criteria

Exclusion criteria: 1. Premature birth (born < 32 weeks of gestation); 2. Congenital heart disease; 3. Pre-existent lung disease (e.g. BPD or CF); 4. T-cel immune deficiency; 5. Pre-treatment with systemic steroids.

Design outcomes

Primary

Measure	Time frame
Length of stay and symptom score.	—

Secondary

Measure	Time frame
Duration of oxygen suppletion, need for ICU-admission.	—

Contacts

Public ContactR. Boogaard

Erasmus Medical Center, Sophia Children’s Hospital, Department of Pediatric Pulmonology, SB-2666, P.O. Box 2060

r.boogaard@erasmusmc.nl+31 (0)10 4636683

Outcome results